177 related articles for article (PubMed ID: 36265846)
1. Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.
Moro PL; Leung J; Marquez P; Kim Y; Wei S; Su JR; Marin M
J Infect Dis; 2022 Oct; 226(Suppl 4):S431-S440. PubMed ID: 36265846
[TBL] [Abstract][Full Text] [Related]
2. A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
Marshall GS; Senders SD; Shepard J; Twiggs JD; Gardner J; Hille D; Hartzel J; Valenzuela R; Stek JE; Helmond FA
Hum Vaccin Immunother; 2016 Aug; 12(8):2188-2196. PubMed ID: 27149048
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for measles, mumps, rubella, and varicella in children.
Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885
[TBL] [Abstract][Full Text] [Related]
4. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
[TBL] [Abstract][Full Text] [Related]
5. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
Nolan T; McIntyre P; Roberton D; Descamps D
Vaccine; 2002 Dec; 21(3-4):281-9. PubMed ID: 12450703
[TBL] [Abstract][Full Text] [Related]
6. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
[TBL] [Abstract][Full Text] [Related]
7. Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries.
Prymula R; Povey M; Brzostek J; Cabrnochova H; Chlibek R; Czajka H; Leviniene G; Man S; Neamtu M; Pazdiora P; Plesca D; Ruzkova R; Stefkovicova M; Usonis V; Verdanova D; Wysocki J; Casabona G; Habib MA
Vaccine; 2021 May; 39(19):2643-2651. PubMed ID: 33858718
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
Leung JH; Hirai HW; Tsoi KK
Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
10. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
[TBL] [Abstract][Full Text] [Related]
12. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.
Yetman RJ; Shepard JS; Duke A; Stek JE; Petrecz M; Klopfer SO; Kuter BJ; Schödel FP; Lee AW
Hum Vaccin Immunother; 2013 Aug; 9(8):1691-7. PubMed ID: 23744509
[TBL] [Abstract][Full Text] [Related]
13. Post-marketing surveillance of adverse events following measles, mumps, rubella and varicella (MMRV) vaccine: retrospecive study in apulia region (ITALY), 2009-2017.
Stefanizzi P; De Nitto S; Patano F; Bianchi FP; Ferorelli D; Stella P; Ancona D; Bavaro V; Tafuri S
Hum Vaccin Immunother; 2020 Aug; 16(8):1875-1883. PubMed ID: 32040350
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
15. Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.
Sukumaran L; McNeil MM; Moro PL; Lewis PW; Winiecki SK; Shimabukuro TT
Clin Infect Dis; 2015 May; 60(10):e58-65. PubMed ID: 25637587
[TBL] [Abstract][Full Text] [Related]
16. Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine.
Weinmann S; Irving SA; Koppolu P; Naleway AL; Belongia EA; Hambidge SJ; Jackson ML; Klein NP; Lewin B; Liles E; Marin M; Smith N; Weintraub E; Chun C
Vaccine; 2020 Aug; 38(37):5880-5884. PubMed ID: 32444193
[TBL] [Abstract][Full Text] [Related]
17. Safety of measles, rubella and mumps vaccines in adults: a prospective cohort study.
Ami N; Eyal N; Asaf B; Chen A; Adi B; Drorit A; Neta P; Hajar D; Stav R; Eli S
J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34101817
[TBL] [Abstract][Full Text] [Related]
18. A combination vaccine against measles, mumps, rubella and varicella.
Knuf M; Faber J; Barth I; Habermehl P
Drugs Today (Barc); 2008 Apr; 44(4):279-92. PubMed ID: 18536786
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of intramuscular versus subcutaneous administration of a combined measles, mumps, rubella, and varicella vaccine to children 12 to 18 months of age.
Haas H; Richard P; Eymin C; Fiquet A; Kuter B; Soubeyrand B
Hum Vaccin Immunother; 2019; 15(4):778-785. PubMed ID: 30481110
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the combined MMRV Priorix-Tetra™ vaccine against varicella in a large Italian region: A case-control study.
Fortunato F; Musco A; Iannelli G; Meola M; Luigi Lopalco P; Martinelli D
Vaccine; 2024 Mar; 42(7):1608-1616. PubMed ID: 38341290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
